A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

What this study is about

This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Who can join (things the study team will check)

✅ You may be able to join if…

• Legal age of consent and at least 18 years old
• Study 1 -
  • BMI ≥ 30 kg/m2 or
  • 25 kg/m2 ≤ BMI < 30 kg/m2 with at least one of the following weight-related comorbidities:
  • Hypertension
  • Prediabetes
  • Dyslipidemia
  • Cardiovascular disease
  • Obstructive sleep apnea.
• Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:
  • Established diagnosis of T2DM
  • Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
• Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
• History of at least one self-reported unsuccessful dietary effort to lose body weight.

🚫 You may not be able to join if…

• Study 1 - Established diagnosis of T1DM or T2DM.
• Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:
  • T1DM
  • HbA1c ≥ 10% (86 mmol/mol) at the screening visit
  • Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
  • Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
• History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
• History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2

Where this trial is running

• Research Site, Birmingham, Alabama, United States
• Research Site, Chandler, Arizona, United States
• Research Site, Lincoln, California, United States
• Research Site, Clearwater, Florida, United States
• Research Site, Woodstock, Georgia, United States
• Research Site, Indianapolis, Indiana, United States
• Research Site, Louisville, Kentucky, United States
• Research Site, Baltimore, Maryland, United States
• Research Site, Potomac, Maryland, United States
• Research Site, Ypsilanti, Michigan, United States
• Research Site, Kansas City, Missouri, United States
• Research Site, Albany, New York, United States

+ 120 more sites.

Who to contact

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07667803.